Key terms

About BTAI

BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest BTAI news

May 14 5:07am ET Hold Rating on Bioxcel Therapeutics Amid Growth Potential and Financial Uncertainties May 10 6:47am ET Bullish Outlook: Bioxcel Therapeutics’ Revenue Surge and Promising Clinical Trials Fuel Buy Rating May 09 7:24am ET BioXcel Therapeutics reports Q1 EPS (87c), consensus (70c) Apr 26 2:11am ET Hold Rating on Bioxcel Therapeutics Amid Strategic and Clinical Trial Uncertainties Apr 23 6:25am ET Buy Rating Reaffirmed for BioXcel Therapeutics Amidst Expansion Opportunities and FDA-Approved IGALMI™ Apr 22 7:22am ET Bioxcel Therapeutics Advances SERENITY Trial and Strategy Apr 22 7:12am ET BioXcel announces plan for evaluating BXCL501 in at-home setting Apr 16 6:31am ET Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX) Apr 16 6:30am ET Analysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI) Apr 15 6:48am ET BioXcel Therapeutics price target lowered to $10 from $11 at H.C. Wainwright Apr 15 6:16am ET Buy Rating Affirmed for Bioxcel Therapeutics Amid Strategic Clinical Trials and Regulatory Potential Mar 25 7:13am ET BioXcel Therapeutics announces $25M registered direct offering Mar 24 2:01am ET Bioxcel Therapeutics Faces Market Estimation Risks Amidst Adoption and Access Challenges Mar 19 8:45am ET Largest borrow rate increases among liquid names Mar 18 6:26am ET Buy Rating Affirmed for BioXcel Therapeutics: FDA Pathway Clear for BXCL501 Expansion Mar 15 8:45am ET Largest borrow rate increases among liquid names Mar 15 7:09am ET BioXcel Therapeutics announces European Patent Office grant Mar 13 7:32am ET BioXcel Therapeutics price target lowered to $7 from $8 at BofA Mar 13 6:39am ET Buy Rating Affirmed for BioXcel Therapeutics Amid Label Expansion and Strong Clinical Prospects Mar 12 8:05am ET Options Volatility and Implied Earnings Moves Today, March 12, 2024 Mar 12 7:09am ET BioXcel Therapeutics provides updates on clinical programs for BXCL501 Mar 12 7:07am ET BioXcel Therapeutics expects cash to fund operations through mid-2024 Mar 12 7:07am ET BioXcel Therapeutics reports Q4 EPS (76c), consensus (91c) Mar 01 8:45am ET Largest borrow rate increases among liquid names Feb 28 8:45am ET Largest borrow rate increases among liquid names Feb 21 7:26am ET BioXcel Therapeutics downgraded to Neutral from Buy at UBS

No recent press releases are available for BTAI

BTAI Financials

1-year income & revenue

Key terms

BTAI Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

BTAI Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms